Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Gilead Sciences shares gain after topping expectations despite lower remdesivir sales
February 3, 2023 9:46 AM ESTGilead Sciences (NASDAQ: GILD) shares rallied in early Friday trading in reaction to the company's latest earnings report, which saw it beat top and bottom-line consensus expectations.
The biopharmaceutical company posted fourth-quarter earnings of $1.67 per share, $0.17 above the analyst consensus estimate of $1.50, while revenue for the quarter came in at $7.4 billion, beating expectations of $6.66 billion.
The company's revenue increased year-over-year, primarily due to increased sales in Oncology, HIV, and hepatitis C virus. However, this was partially offset by... More
Gilead Sciences (GILD) Tops Q4 EPS by 17c; Guides
February 2, 2023 4:06 PM ESTGilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.67, $0.17 better than the analyst estimate of $1.50. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.66 billion.
GUIDANCE:
Gilead Sciences sees FY2023 EPS of $6.60-$7.00, versus the consensus of... More
